Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease ...
Inc.(NASDAQ: REGN) andSanofitoday announced that the second Dupixent®(dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that Dupixent significantly reduced (34%) exacerbations, confirming positiveresultsfrom the landmark Phase 3 BOREAS...
Positive Phase 3 results presented for Dupixent® (dupilumab) show significant improvement on multiple measures of disease severity in adolescents with moderate-to-severe atopic dermatitisAdverse events that were observed more frequently with Dupixent included injection site ...
The New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents treated with Dupixent® 300 mg weekly experienced significant improvements in signs and symptoms of eo...
December 17, 2024 Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Read the Press Release December 17, 2024 Press Release: Availability of the Q4 2024 Aide-mémoire Read the Press Release See all press releasesFollow...